Marizomib reduced viability in LN229 and U118 glioblastoma cells after 24–48 h. MTT-derived IC50 values were 217.3 and 126.9 nM for LN229 at 24 and 48 h, respectively, and 297.0 and 99.03 nM for U118. ATP-based measurements supported the viability response. [2]
In LN229 and U118 cells, 50–100 nM marizomib increased ER-stress-associated markers. The same study found no significant ROS increase and no detected increase in the assessed autophagy markers under its conditions. These observations support a model-specific stress response; they do not establish ER stress as necessary for cell death. [2]
Subunit-dependent inhibition of purified human 20S proteasome
Biochemical assay · Purified human constitutive 20S proteasome with PA28α activator [1]
Marizomib inhibited β5 most potently under this assay timing, with higher IC50 values for β2 and β1. Figure values are mean ± SD from three technical replicates, not independent biological replicates.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–12.5 μM concentration series
- Exposure duration
- IC50 calculated 60–90 min after reaction initiation
- Method
- Subunit-selective fluorogenic activity assay at 37 °C; 1 nM h20S with 100 nM PA28α
- Co-treatment
- None
- Reported limits
- Inhibitor vehicle and enzyme–inhibitor preincubation time are not specified in the selected assay methods; substrate prefix differs between Methods and Figure 2 for β5.
Methods and source locations
Compound reported in the paper: Marizomib; Compound label in the paper: MZB
Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.
Results 2.1; Figure 2 and caption; Materials preface; Methods 4.1
β5 chymotrypsin-like proteolytic activity: LLVY-AMC fluorogenic substrate; mean ± SD, 3 technical replicates — Figure 2 labels/caption; Results 2.1; Methods 4.1
β2 trypsin-like proteolytic activity: Z-VLR-AMC fluorogenic substrate; mean ± SD, 3 technical replicates — Figure 2 labels/caption; Results 2.1; Methods 4.1
β1 caspase-like proteolytic activity: Z-LLE-AMC fluorogenic substrate; mean ± SD, 3 technical replicates — Figure 2 labels/caption; Results 2.1; Methods 4.1
Covalent binding at human proteasome catalytic sites
Biochemical assay · Marizomib-bound purified human 20S proteasome, single-particle cryo-EM [1]
The reported human 20S reconstruction places marizomib covalently attached to catalytic Thr1 at β1, β2 and β5 sites in both β-rings. This is structural evidence of covalent engagement; the experiment does not measure cellular potency or inhibitor washout kinetics.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM marizomib with approximately 0.6 μM h20S
- Exposure duration
- 1 h at room temperature before cooling
- Method
- Single-particle cryo-EM and model refinement
- Co-treatment
- None
- Reported limits
- No matched unbound cryo-EM sample is reported in these sections; comparison used the existing human 20S model PDB 7PG9. SI validation plots were not retrieved.
Methods and source locations
Compound reported in the paper: Marizomib; Compound label in the paper: MZB
Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.
Results 2.2–2.3; Figure 3 and caption; Materials preface; Methods 4.2–4.4
Binding to β1, β2 and β5 catalytic sites: Cryo-EM density and fitted ligand model, Figure 3B–C — Results 2.2–2.3; Figure 3B–C; Methods 4.2–4.4
Viability reduction in LN229 and U118 glioblastoma cells
Cell-based study · Human LN229 and U118 glioblastoma cell lines [2]
Marizomib reduced MTT viability and ATP-based signal after 24 or 48 h. MTT-derived IC50 values differed by cell line and exposure duration. Bortezomib and carfilzomib were separate comparators, not combinations.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5–1000 nM
- Exposure duration
- 24 and 48 h
- Method
- MTT viability with complementary CellTiter-Glo ATP assay
- Vehicle
- DMSO stock; vehicle controls contained 0.5% DMSO; treatment DMSO reported below 1%
- Co-treatment
- None
- Reported limits
- Exact DMSO matching for each treatment concentration is not given. Figure 1 does not provide uncertainty intervals for fitted IC50 values.
Methods and source locations
Compound reported in the paper: Marizomib; Compound label in the paper: MZB
Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.
Results 2.1; Figure 1A–B, E and caption; Methods 4.1–4.4, 4.10
LN229 MTT viability: Nonlinear regression, GraphPad Prism 9; values transcribed from Figure 1E table — Figure 1E LN229 table; Results 2.1; Methods 4.2–4.4, 4.10
U118 MTT viability: Nonlinear regression, GraphPad Prism 9; values transcribed from Figure 1E table — Figure 1E U118 table; Results 2.1; Methods 4.2–4.4, 4.10
ER-stress markers with no significant measured ROS increase
Cell-based study · Human LN229 and U118 glioblastoma cell lines [2]
ER-stress markers increased, whereas measured ROS did not significantly change. ERO1α and the assessed autophagy markers did not show the increases expected for those pathways. These findings limit claims that ROS elevation or autophagy is a universal response to marizomib.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 and 100 nM
- Exposure duration
- 24 h exposure; ROS method additionally specifies 6 h after substrate addition
- Method
- Western blot, RT-qPCR and ROS-Glo H2O2 luminescence assay
- Vehicle
- DMSO vehicle control: 0.5%; treatment DMSO below 1%
- Co-treatment
- None
- Reported limits
- Figure 3 labels ROS as the 24 h treatment experiment; Methods 4.7 adds a 6 h substrate-incubation step. Exact total timing and dose-specific vehicle matching are not clarified. No stress-pathway inhibition control is reported in the selected stress experiment.
Methods and source locations
Compound reported in the paper: Marizomib; Compound label in the paper: MZB
Evidence applies to the paper-reported material and model; it does not validate an Adooq lot or establish clinical efficacy.
Results 2.3; Figure 3A–D and caption; Methods 4.1–4.2, 4.7–4.10; Discussion ROS/autophagy paragraphs
ER-stress-associated protein and transcript responses: Representative blots normalized by β-tubulin loading controls and RT-qPCR relative to vehicle; mean ± SD, three independent experiments run in triplicate per Methods — Figure 3A–B; Results 2.3; Methods 4.8–4.10
Measured ROS and assessed autophagy markers: ROS-Glo H2O2, representative blots and RT-qPCR; vehicle-controlled — Figure 3B–D; Results 2.3; Methods 4.7–4.10